Structure Therapeutics Inc ADR GPCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GPCR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $38.98
- Day Range
- $37.85–39.46
- 52-Week Range
- $21.79–75.02
- Bid/Ask
- $38.27 / $39.97
- Market Cap
- $1.81 Bil
- Volume/Avg
- 972,594 / 584,328
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 93
- Website
- https://www.structuretx.com
Valuation
|
Metric
|
GPCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.99 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GPCR
|
|---|---|
Quick Ratio | 18.89 |
Current Ratio | 19.14 |
Interest Coverage | — |
Quick Ratio
GPCR
Profitability
|
Metric
|
GPCR
|
|---|---|
Return on Assets (Normalized) | −31.98% |
Return on Equity (Normalized) | −41.48% |
Return on Invested Capital (Normalized) | −47.82% |
Return on Assets
GPCR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vvjcwwxyv | Cnqq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qtfhlqfd | Rycmhpr | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dqxswtytk | Dvfhhl | $97.8 Bil | |
MRNA
| Moderna Inc | Pjjkkkq | Xsdl | $41.3 Bil | |
ARGX
| argenx SE ADR | Khktjldl | Qkc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hzymvzwp | Fmf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cndftny | Qpwxkh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fzgcgzxsv | Byfqz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zrjlzkrq | Tpzkmg | $12.5 Bil | |
INCY
| Incyte Corp | Vkwvvdth | Rlrjt | $11.6 Bil |